Cantor Fitzgerald initiated coverage of Pelthos Therapeutics (PTHS) with an Overweight rating and $50 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTHS:
- Pelthos Therapeutics doses first patient in CT2000 trial
- Pelthos Therapeutics Inc trading resumes
- Pelthos Therapeutics Inc trading halted, volatility trading pause
- Pelthos Therapeutics price target raised to $62 from $60 at Oppenheimer
- Pelthos Highlights 2025 Results and Portfolio Expansion Progress